WB
The startup develops small molecule prodrugs that activate into cytotoxic agents through the overexpression of specific intracellular enzymes in cancer cells. This approach targets common cancers with significant patient populations and high unmet medical needs, providing selective therapy options for patients with limited treatment alternatives.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops small molecule prodrugs that activate into cytotoxic agents through the overexpression of specific intracellular enzymes in cancer cells. This approach targets common cancers with significant patient populations and high unmet medical needs, providing selective therapy options for patients with limited treatment alternatives.